IP Group and Penn Medicine have both returned to back a series A round for Carisma Therapeutics, the Pennsylvania spinout formerly known as Carma.

Carisma Therapeutics, a US-based immunotherapy developer spun out from University of Pennsylvania, closed a $53m series A round today that featured Penn Medicine, the university-owned health system.
Commercialisation firm IP Group also contributed to the round, which was co-led by AbbVie Ventures, the corporate venturing division of pharmaceutical firm AbbVie, and VC firm HealthCap.
Other investors included MRL Ventures Fund, operated by pharmaceutical company Merck & Co’s Merck Research Laboratories division, as well as Grazia Equity, Wellington Partners,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?